Dr. David D. Wright, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Florida College of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,266
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of South Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME75017 -
Hematology (Internal Medicine) Physician
FL license ME75017
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Tampa General Hospital Tampa, FL
- Adventhealth Tampa Tampa, FL
- Adventhealth Wesley Chapel Wesley Chapel, FL
- Adventhealth Sebring Sebring, FL
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,266
- Services billed
- 280,435
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, iron sucrose, 1 mg | 45,800 | 72 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 33,150 | 32 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 22,590 | 75 |
| Injection, denosumab, 1 mg | 17,460 | 113 |
| Injection, aprepitant, 1 mg | 15,730 | 28 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 10,680 | 12 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 6,782 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6,476 | 67 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,994 | 949 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,892 | 57 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Tampa, FL | 206 |
| Revlimid (lenalidomide) | 138 |
| Eliquis (apixaban) Other prescribers in Tampa, FL | 105 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Tampa, FL | 91 |
| Anastrozole Other prescribers in Tampa, FL | 90 |
| Oxycodone Hcl Other prescribers in Tampa, FL | 61 |
| Tamoxifen Citrate Other prescribers in Tampa, FL | 56 |
| Xarelto (rivaroxaban) Other prescribers in Tampa, FL | 44 |
| Enoxaparin Sodium Other prescribers in Tampa, FL | 38 |
| Tramadol Hcl Other prescribers in Tampa, FL | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 45 companies reported 198 payments worth $4,795 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $374 |
|---|---|
| Tersera Therapeutics LLC | $369 |
| Incyte Corporation | $340 |
| Gilead Sciences, Inc. | $316 |
| E.r. Squibb & Sons, L.l.c. | $265 |
| AstraZeneca Pharmaceuticals LP | $264 |
| Celgene Corporation | $257 |
| Pfizer Inc. | $248 |
| Food and Beverage | $4,795 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $787,278 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca Pharmaceuticals LP - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
AbbVie Inc. · Completed · NCT02947347 - DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
AstraZeneca Pharmaceuticals LP - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
AstraZeneca UK Limited - A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT03682536 - A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.